General Partner Inc. Buys Shares of 365 Hologic, Inc. (NASDAQ:HOLX)

General Partner Inc. acquired a new position in Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 365 shares of the medical equipment provider’s stock, valued at approximately $26,000.

A number of other hedge funds also recently bought and sold shares of HOLX. FMR LLC lifted its position in shares of Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the last quarter. Black Creek Investment Management Inc. boosted its position in shares of Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after acquiring an additional 885,524 shares during the period. Mackenzie Financial Corp grew its stake in shares of Hologic by 1,023.3% in the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after acquiring an additional 815,960 shares during the last quarter. Marshall Wace LLP bought a new position in Hologic during the second quarter worth $39,427,000. Finally, The Manufacturers Life Insurance Company increased its position in Hologic by 21.6% during the second quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock worth $188,243,000 after acquiring an additional 450,190 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on HOLX. JPMorgan Chase & Co. increased their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Royal Bank of Canada lifted their target price on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. Raymond James raised their price objective on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Needham & Company LLC restated a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Thursday, December 19th. Finally, UBS Group lifted their price target on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $89.50.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.75% of the stock is currently owned by corporate insiders.

Hologic Price Performance

HOLX stock traded up $0.35 during trading on Friday, hitting $72.09. 156,468 shares of the stock traded hands, compared to its average volume of 632,277. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The stock has a market cap of $16.36 billion, a price-to-earnings ratio of 21.65, a P/E/G ratio of 2.32 and a beta of 0.96. Hologic, Inc. has a one year low of $70.36 and a one year high of $84.67. The company has a 50 day simple moving average of $76.87 and a 200 day simple moving average of $78.43.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period in the previous year, the business earned $0.89 EPS. Hologic’s revenue was up 4.5% compared to the same quarter last year. Equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.